摘要
目的观察重组人促红细胞生成素(erythropoietin,EPO)治疗慢性心力衰竭(chronic heart failure,CHF)患者的临床疗效,并评估其药物安全性。方法依据相应纳入及排除标准入选住院期间CHF患者80例,按随机数字表法随机分为EPO治疗组和对照组。在常规CHF治疗基础上,EPO组加用依普定,对照组为单纯常规CHF药物治疗。共双盲治疗两个月。比较两组患者用药前后临床症状、心功能情况及远期预后。结果 EPO治疗组治疗两个月后,患者运动耐量显著提高、心功能有所改善,心率显著低于对照组,尿量较对照组增多,左心室射血分数较对照组提高,差异有统计学意义(P<0.05);EPO治疗组CHF急性加重发生率显著低于对照组,差异有统计学意义(P<0.05);但两组治疗前、后左心室舒张末内径(LVDD)及左心室收缩末内径(LVSD)比较,差异无统计学意义(P>0.05)。不良反应为部分患者应用EPO一个月后出现血压升高,但与对照组比较,差异无统计学意义(P>0.05)。结论 EPO作为CHF的辅助治疗药物,治疗效果显著,且安全可行。
Objectives To observe the efficacy and safety of erythropoietin （EPO） administration in patients with chronic heart failure （CHF）. Methods According to corresponding inclusion and exclusion criteria, a total of 80 hospitalized patients with CHF [ New York Heart Association （NYHA） functional class Ⅲ-Ⅳ] were randomly divided into EPO treatment group and control group. On the basis of the conventional CHF therapy, patients in EPO group received Epogen, and patients in control group received conventional CHF medical treatment. Double-blind treatment with EPO was conducted for two months. Clinical symptoms, cardiac function and long-term prognosis of patients with CHF before and after treatment were assessed. Results After 2 months＇ treatment, shortness of breath after exercise significantly reduced and exercise tolerance increased in EPO group. Furthermore, in EPO-treated patients, cardiac function improved, heart rate reduced, urine output increased and left ventricular ejection fraction （LVEF） increased （P〈0.05） ; incidence of acute exacerbation of CHF was significantly lower than that in control group （P〈0.05）, but left ventricular end-diastolic diameter （LVDD） and left ventricular end-systolic diameter （LVSD） did not show great difference before and after treatment （P〉0.05） in the two groups. In some patients, blood pressure increased after application of EPO in one month, but the difference was not significant （P〉0.05）. Conclusions As an adjuvant therapy, the efficacy of EPO in CHF is significant, and this drug is safe.
出处
《岭南心血管病杂志》
2016年第1期59-61,77,共4页
South China Journal of Cardiovascular Diseases
